ACADIA Pharmaceuticals Investor Relations Material
Latest events
Q4 2024
ACADIA Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from ACADIA Pharmaceuticals Inc
Access all reports
ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on improving the lives of patients with serious central nervous system disorders. The Company has a clinical program to assess the safety, efficacy and pharmacokinetic profile of pimavanserin (RE-021), an investigational drug that acts as a selective serotonin 5-hydroxytryptamine 2A receptor inverse agonist (SSRI) to study the central serotonergic system pharmacology and physiology in healthy volunteers and patients with Parkinson's disease psychosis (PDP).
Key slides for ACADIA Pharmaceuticals Inc
Q4 2024
ACADIA Pharmaceuticals Inc
Corporate Presentation
ACADIA Pharmaceuticals Inc
Latest articles
)
Moncler: From the Mountains to the Runway
The story of Moncler, all the way from its beginnings in the Alps to its journey to some of the most prestigious runways in the world.
16 Apr 2025
)
eToro: Innovation, Growth, and IPO Plans
eToro was founded in 2007 and has grown into a global trading platform with over 40 million users and an extensive offering across several asset classes.
10 Apr 2025
)
Yum! Brands: The Company Behind Pizza Hut, KFC, and Taco Bell
Yum! Brands started at PepsiCo in the 1970s and is home to some of the most well-known brands in the world, such as Pizza Hut, KFC, and Taco Bell.
9 Apr 2025
Ticker symbol
ACAD
Country
🇺🇸 United States